Cost Insights: Breaking Down Travere Therapeutics, Inc. and Dyne Therapeutics, Inc.'s Expenses

Biotech Expense Trends: Travere vs. Dyne

__timestampDyne Therapeutics, Inc.Travere Therapeutics, Inc.
Wednesday, January 1, 20141145000000570979
Thursday, January 1, 201520280000002185000
Friday, January 1, 201622810000004554000
Sunday, January 1, 201729320000003605000
Monday, January 1, 2018240005527000
Tuesday, January 1, 20192710005234000
Wednesday, January 1, 20207000006126000
Friday, January 1, 202110880006784000
Saturday, January 1, 202233450007592000
Sunday, January 1, 2023246100011450000
Loading chart...

In pursuit of knowledge

Cost Insights: A Comparative Analysis of Biotech Giants

Unveiling the Expense Trajectories of Travere and Dyne Therapeutics

In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the annual cost of revenue trends for Travere Therapeutics, Inc. and Dyne Therapeutics, Inc. from 2014 to 2023.

Travere Therapeutics has shown a steady increase in its cost of revenue, peaking in 2023 with a 100% rise from its 2014 figures. This growth reflects the company's expanding operations and investment in research and development. In contrast, Dyne Therapeutics experienced a volatile trajectory, with a significant spike in 2017, followed by a sharp decline in subsequent years. By 2023, Dyne's costs had reduced by over 99% from their 2017 peak, indicating strategic cost management or shifts in operational focus.

These insights provide a window into the financial strategies of these biotech leaders, offering valuable perspectives for potential investors.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025